Initiation of Toll-like Receptor Signaling
Toll 样受体信号传导的启动
基本信息
- 批准号:7217499
- 负责人:
- 金额:$ 28.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAntigen PresentationAntigensArthritisAsthmaAtherosclerosisAutoimmunityCell physiologyCell surfaceCellsComplexDiscriminationDominant-Negative MutationElementsEnsureEventFamilyFamily memberFluorescence Resonance Energy TransferFractionationFungal ComponentsGenesGoalsHost DefenseImmune System DiseasesImmune responseImmune systemIndividualInfectionInflammationInflammatoryInvadedLigandsLightMediatingMembraneMicroscopyMolecularMolecular StructureMovementNatural ImmunityNaturePhagocytosisPinocytosisPrincipal InvestigatorProcessRangeReceptor SignalingResearchRoleSepsisSignal TransductionSpecificitySystemT-LymphocyteTLR1 geneTLR2 geneTLR6 geneToll-Like Receptor 1Toll-Like Receptor 2Toll-like receptorsViralacquired immunitybasedefense responseextracellularkillingsmembermicrobialpathogenreceptorresearch studyresponsesmall hairpin RNAtrafficking
项目摘要
DESCRIPTION (provided by applicant): The innate immune system performs the critical task of immediately protecting the host from infection and generating responses that alert and guide the actions of acquired immunity. Toll-like receptors (TLRs) are essential elements of innate immunity which upon direct recognition of microbial, fungal and viral components activate cellular events leading to inflammation, direct killing of the pathogen, and enhanced antigen presentation. Their essential role in inducing and regulating these events, is evidenced by their direct association with a variety of immune disorders ranging from sepsis, atherosclerosis, arthritis, asthma and autoimmunity. Among the ten member TLR family, TLR2 requires TLR1 or TLR6 to recognize, discriminate and initiate responses to a wide variety of rnicrobial components. Host responses are mediated by the two cytoplasmic proximal adaptor molecules known as MyD88 and TIRAP/MAL. The long term goal of this project is to define the mechanism by which this subfamily of TLRs recognize their agonists, initiate cellular responses, and coordinate these responses at the subcellular and molecular level. The specific aims are 1) To define the precise role of TLRs 1 and 6 in recognition of microbial and fungal components as well as the extracellular regions of the receptors involved, 2) To determine the intracellular trafficking and physical interactions among TLRs 1, 2 and 6 and the proximal adaptor molecules MyD88 and TIRAP/ MAL upon agonist-mediated cell activation, and 3) To define the role of proximal signaling events; on the observed cell surface colocalization of TLRs and other TLR-associated endocytic trafficking events. The specific function of TLRs, with respect to agonist discrimination as well as the structural basis of this discrimination, are assessed through the use of synthetic; agonists and receptor domain swapping experiments. The localization of TLRs and adaptors are assessed through direct microscopy including FRET, membrane fractionation, and pharmacalogic agents. The effect of dominant negative molecules, shRNA and pharmacalogic agents address the role of signaling events on intracellular TLR trafficking.
描述(由申请人提供):先天免疫系统执行立即保护宿主免受感染并产生警报和指导获得性免疫作用的反应的关键任务。Toll样受体(TLR)是先天免疫的基本要素,其在直接识别微生物、真菌和病毒组分后激活细胞事件,导致炎症、直接杀死病原体和增强的抗原呈递。它们在诱导和调节这些事件中的重要作用通过它们与多种免疫病症的直接关联来证明,所述免疫病症包括败血症、动脉粥样硬化、关节炎、哮喘和自身免疫。在TLR家族的10个成员中,TLR 2需要TLR 1或TLR 6来识别、区分和启动对多种抗菌成分的应答。本项目的长期目标是确定TLR亚家族识别其激动剂、启动细胞应答并在亚细胞和分子水平协调这些应答的机制。具体目的是1)确定TLR 1和6在识别微生物和真菌组分以及所涉及的受体的细胞外区域中的精确作用,2)确定在激动剂介导的细胞活化后TLR 1、2和6与近端衔接分子MyD 88和TIRAP/ MAL之间的细胞内运输和物理相互作用,和3)确定近端信号传导事件对观察到的TLR的细胞表面共定位和其它TLR相关的内吞运输事件的作用。TLR的特定功能,激动剂歧视以及这种歧视的结构基础,通过使用合成的激动剂和受体结构域交换实验进行评估。TLR和衔接子的定位通过直接显微镜进行评估,包括FRET、膜分离和药理学试剂。显性负性分子、shRNA和药理学试剂的作用解决了信号传导事件对细胞内TLR运输的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Ian Tapping其他文献
Richard Ian Tapping的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Ian Tapping', 18)}}的其他基金
Regulation of B cell lymphocyte responses by TLR10
TLR10 调节 B 细胞淋巴细胞反应
- 批准号:
8414818 - 财政年份:2012
- 资助金额:
$ 28.12万 - 项目类别:
Regulation of B cell lymphocyte responses by TLR10
TLR10 调节 B 细胞淋巴细胞反应
- 批准号:
8223664 - 财政年份:2012
- 资助金额:
$ 28.12万 - 项目类别:
Genetic and molecular basis of host resistance to Yersinia pestis.
宿主对鼠疫耶尔森氏菌的抗性的遗传和分子基础。
- 批准号:
8422971 - 财政年份:2012
- 资助金额:
$ 28.12万 - 项目类别:
Regulation of B cell lymphocyte responses by TLR10
TLR10 对 B 细胞淋巴细胞反应的调节
- 批准号:
8791296 - 财政年份:2012
- 资助金额:
$ 28.12万 - 项目类别:
Genetic and molecular basis of host resistance to Yersinia pestis.
宿主对鼠疫耶尔森氏菌的抗性的遗传和分子基础。
- 批准号:
8303710 - 财政年份:2012
- 资助金额:
$ 28.12万 - 项目类别:
The Role of Host B Lymphocytes in Yersinia Pathogenesis
宿主 B 淋巴细胞在耶尔森氏菌发病机制中的作用
- 批准号:
7173346 - 财政年份:2005
- 资助金额:
$ 28.12万 - 项目类别:
The Role of Host B Lymphocytes in Yersinia Pathogenesis
宿主 B 淋巴细胞在耶尔森氏菌发病机制中的作用
- 批准号:
7006992 - 财政年份:2005
- 资助金额:
$ 28.12万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 28.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 28.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 28.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




